UCBJF:OTCMKTS
UCB SA
US$ 240.24
arrow_upward
+1.82%(+4.30) Siku 1
15 Okt, 16:00:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya UCBJF...
Fungua
US$ 240.24
Juu
US$ 240.24
Chini
US$ 240.24
Mtaji wa soko
40.07B
Wastani wa kiasi cha mauzo
139.00
Kiasi cha mauzo ya hisa
10.00
Juu kwa wiki 52
US$ 345.39
Chini kwa wiki 52
US$ 219.60
Beta
0.58
Hisa za wawekezaji
194.51M
Idadi ya wafanyakazi
elfu 9
Fungua
US$ 240.24
Juu
US$ 240.24
Chini
US$ 240.24
Mtaji wa soko
40.07B
Wastani wa kiasi cha mauzo
139.00
Kiasi cha mauzo ya hisa
10.00
Juu kwa wiki 52
US$ 345.39
Chini kwa wiki 52
US$ 219.60
Beta
0.58
Hisa za wawekezaji
194.51M
Idadi ya wafanyakazi
elfu 9
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 21 zilizopita
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Wasifu
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Kuhusu UCB SA
Afisa Mkuu Mtendaji (CEO)Jean-Christophe Tellier
Wafanyakazielfu 9
Lilianzishwa18 Jan 1928
Makao makuu-
Sekta-
Tovutiucb.com